<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190150</url>
  </required_header>
  <id_info>
    <org_study_id>FE999304 CS01</org_study_id>
    <nct_id>NCT01190150</nct_id>
  </id_info>
  <brief_title>Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding</brief_title>
  <acronym>PREA</acronym>
  <official_title>Randomized, 2-way Crossover, Pharmacokinetic Study of Lysteda (Xanodyne Modified-Immediate Release Tranexamic Acid) Tablets at 2 Doses in Fasting Adolescent Females With Evidence of Heavy Menstrual Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 4, randomized, 2-way crossover, pharmacokinetic study of Lysteda (tranexamic
      acid) tablets administered as single doses of 0.65 g and 1.3 g in fasting adolescent female
      subjects ages 12-16 years with heavy menstrual bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentrations Level (Cmax)</measure>
    <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
    <description>Cmax is the maximum measured plasma concentration over the time-span specified.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-normalized Maximum Concentrations Level (Cmax)</measure>
    <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
    <description>Cmax is the maximum measured plasma concentration over the time-span specified and normalized to the 1.3 g dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration Level (Tmax)</measure>
    <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
    <description>Time of the maximum measured plasma concentration. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From 0 to the Last Time Point (AUC0-t)</measure>
    <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
    <description>The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration, as calculated by the linear trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Normalized Area Under the Concentration Versus Time Curve From 0 to the Last Time Point (AUC0-t)</measure>
    <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
    <description>The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration normalized to the 1.3 g dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From 0 to Infinity (AUCinf)</measure>
    <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
    <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUCinf is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Normalized Area Under the Concentration Versus Time Curve From 0 to Infinity (AUCinf)</measure>
    <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
    <description>Dose-normalized AUCinf is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, normalized to the 1.3 g dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Ratio of AUC0-t to AUCinf</measure>
    <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
    <description>Comparison of AUC0-t to AUCinf by creating a ratio.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-life (t ½)</measure>
    <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
    <description>Apparent first-order terminal elimination half life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 1 up to week 4</time_frame>
    <description>Treatment-emergent AEs are summarized by total participants with TEAEs, participants with serious TEAEs, participants with TEAEs deemed by the investigator to be related to treatment, and participants who experienced TEAEs that caused permanent discontinuation from the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>0.65 g / 1.3 g tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of 0.65 g tranexamic acid on Day 1 and a single dose of 1.3 g tranexamic acid on Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.3 g / 0.65 g tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single dose of 1.3 g tranexamic acid on Day 1 and a single dose of 0.65 g tranexamic acid on Day 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tranexamic acid</intervention_name>
    <description>Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.</description>
    <arm_group_label>0.65 g / 1.3 g tranexamic acid</arm_group_label>
    <arm_group_label>1.3 g / 0.65 g tranexamic acid</arm_group_label>
    <other_name>Lysteda</other_name>
    <other_name>modified-immediate release tranexamic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy non-smoking (for at least 3 months) adolescent females 12-16 years
             of age with a history of at least 1 year of cyclic heavy menstrual bleeding (HMB)

          -  Subjects must report regularly occurring menstrual periods ≤10 days in duration, with
             21-45 days from the start of one period to the start of the next menstrual period

          -  Diagnosis of HMB based on the medical judgment of the Principal Investigator and will
             include the following criteria:

               1. Laboratory (including a bleeding disorders work-up) and Physical Findings;

               2. Limitations in Activities of Daily Living (ADL);

               3. Soiling, Staining and Clotting;

               4. Sanitary product usage and extent of MBL using a patient reported pictorial blood
                  assessment chart (PBAC).

          -  Subjects should either be sexually inactive (abstinent) or be using one of the
             following acceptable birth control methods and agree to continue its use throughout
             the study:

               -  copper intrauterine device (IUD) in place for at least 3 months;

               -  barrier methods (condom, diaphragm) with spermicide for at least 1 month prior to
                  the first dose and throughout the study.

          -  Negative pregnancy test results

          -  Subject's legally authorized representative (e.g., parent, guardian) must voluntarily
             sign a parental permission/informed consent form (ICF), and the subject must sign an
             assent, before the conduct of any study procedure

        Exclusion Criteria:

          -  Breast-feeding, or a history of abortion in the last 6 months

          -  Known bleeding or coagulation disorders based on medical history and/or laboratory
             results

          -  Known systemic hematologic diseases (e.g., all types of sickle-cell disease,
             thalassemia of all types, multiple myeloma, hemolytic anemia)

          -  Clinical evidence of any significant chronic illness, including cardiovascular, renal,
             neurologic, hepatic, endocrine, gastric, central nervous system disease, any
             psychiatric illness which could affect the efficacy or safety of study medication

          -  Subjects treated with systemic steroids in the last 1 month or hormonal treatment in
             the last 3 months

          -  A history or presence of any drug abuse or alcohol abuse within the last 1 year

          -  History of subarachnoid hemorrhage.

          -  Active thromboembolic disease; history of thrombosis or thromboembolism, including
             retinal vein or artery occlusion; an intrinsic risk of thrombosis or thromboembolism

          -  Use of vaginal hormone products (rings, creams, and gels) within 4 weeks prior to
             screening. Use of oral estrogen-, progestin-, or selective estrogen receptor within 8
             weeks prior to screening. Use of Lupron (3-month depot injection), estrogen pellet, or
             long-acting progestin injectables within 6 months prior to screening

          -  Subjects whose sitting blood pressure is less than 90/60 mmHg at screening

          -  Subjects whose pulse is lower than 50 b.p.m. at screening

          -  Subjects whose PR interval is &gt;200 msec at screening and prior to dosing

          -  Subjects whose QTc interval &gt;450 msec

          -  Subjects with positive tests for hepatitis B, C, or human immunodeficiency virus (HIV)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2010</study_first_posted>
  <results_first_submitted>May 30, 2012</results_first_submitted>
  <results_first_submitted_qc>May 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2012</results_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cyclic Heavy Menstrual Bleed</keyword>
  <keyword>Menorraghia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.65 g / 1.3 g Tranexamic Acid</title>
          <description>Participants received a single dose of 0.65 g tranexamic acid on Day 1 and a single dose of 1.3 g tranexamic acid on Day 8.</description>
        </group>
        <group group_id="P2">
          <title>1.3 g / 0.65 g Tranexamic Acid</title>
          <description>Participants received a single dose of 1.3 g tranexamic acid on Day 1 and a single dose of 0.65 g tranexamic acid on Day 8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11">Randomized, as well as Safety and PK populations</participants>
                <participants group_id="P2" count="9">Randomized, as well as Safety and PK populations</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Difficulty in adherence</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.65 g / 1.3 g Tranexamic Acid</title>
          <description>Participants received a single dose of 0.65 g tranexamic acid on Day 1 and a single dose of 1.3 g tranexamic acid on Day 8.</description>
        </group>
        <group group_id="B2">
          <title>1.3 g / 0.65 g Tranexamic Acid</title>
          <description>Participants received a single dose of 1.3 g tranexamic acid on Day 1 and a single dose of 0.65 g tranexamic acid on Day 8.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.5" spread="1.13"/>
                    <measurement group_id="B2" value="14.3" spread="1.32"/>
                    <measurement group_id="B3" value="14.4" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentrations Level (Cmax)</title>
        <description>Cmax is the maximum measured plasma concentration over the time-span specified.</description>
        <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
        <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>0.65 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
          </group>
          <group group_id="O2">
            <title>1.3 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentrations Level (Cmax)</title>
          <description>Cmax is the maximum measured plasma concentration over the time-span specified.</description>
          <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9967" spread="2.08058"/>
                    <measurement group_id="O2" value="10.9868" spread="3.38910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose-normalized Maximum Concentrations Level (Cmax)</title>
        <description>Cmax is the maximum measured plasma concentration over the time-span specified and normalized to the 1.3 g dose.</description>
        <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
        <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>0.65 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
          </group>
          <group group_id="O2">
            <title>1.3 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized Maximum Concentrations Level (Cmax)</title>
          <description>Cmax is the maximum measured plasma concentration over the time-span specified and normalized to the 1.3 g dose.</description>
          <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9933" spread="4.16115"/>
                    <measurement group_id="O2" value="10.9868" spread="3.38910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Concentration Level (Tmax)</title>
        <description>Time of the maximum measured plasma concentration. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.</description>
        <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
        <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>0.65 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
          </group>
          <group group_id="O2">
            <title>1.3 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration Level (Tmax)</title>
          <description>Time of the maximum measured plasma concentration. If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.</description>
          <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.17" spread="0.642"/>
                    <measurement group_id="O2" value="3.11" spread="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve From 0 to the Last Time Point (AUC0-t)</title>
        <description>The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration, as calculated by the linear trapezoidal method.</description>
        <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
        <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>0.65 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
          </group>
          <group group_id="O2">
            <title>1.3 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From 0 to the Last Time Point (AUC0-t)</title>
          <description>The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration, as calculated by the linear trapezoidal method.</description>
          <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
          <units>μg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8067" spread="10.56742"/>
                    <measurement group_id="O2" value="56.7935" spread="19.27448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Normalized Area Under the Concentration Versus Time Curve From 0 to the Last Time Point (AUC0-t)</title>
        <description>The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration normalized to the 1.3 g dose.</description>
        <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
        <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>0.65 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
          </group>
          <group group_id="O2">
            <title>1.3 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Area Under the Concentration Versus Time Curve From 0 to the Last Time Point (AUC0-t)</title>
          <description>The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration normalized to the 1.3 g dose.</description>
          <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
          <units>μg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6134" spread="21.13483"/>
                    <measurement group_id="O2" value="56.7935" spread="19.27448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve From 0 to Infinity (AUCinf)</title>
        <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUCinf is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
        <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
        <population>Plasma PK population including all participants with three or more non-zero plasma concentrations. One participant withdrew on Day 7 and did not meet the requisite samples required for this PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>0.65 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
          </group>
          <group group_id="O2">
            <title>1.3 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From 0 to Infinity (AUCinf)</title>
          <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUCinf is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
          <population>Plasma PK population including all participants with three or more non-zero plasma concentrations. One participant withdrew on Day 7 and did not meet the requisite samples required for this PK parameter.</population>
          <units>μg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8016" spread="10.71237"/>
                    <measurement group_id="O2" value="61.2591" spread="15.45770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Normalized Area Under the Concentration Versus Time Curve From 0 to Infinity (AUCinf)</title>
        <description>Dose-normalized AUCinf is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, normalized to the 1.3 g dose.</description>
        <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
        <population>Plasma PK population including all participants with three or more non-zero plasma concentrations. One participant withdrew on Day 7 and did not meet the requisite samples required for this PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>0.65 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
          </group>
          <group group_id="O2">
            <title>1.3 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Normalized Area Under the Concentration Versus Time Curve From 0 to Infinity (AUCinf)</title>
          <description>Dose-normalized AUCinf is calculated as the sum of AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, normalized to the 1.3 g dose.</description>
          <population>Plasma PK population including all participants with three or more non-zero plasma concentrations. One participant withdrew on Day 7 and did not meet the requisite samples required for this PK parameter.</population>
          <units>μg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6032" spread="21.42474"/>
                    <measurement group_id="O2" value="61.2591" spread="15.45770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Ratio of AUC0-t to AUCinf</title>
        <description>Comparison of AUC0-t to AUCinf by creating a ratio.</description>
        <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
        <population>Plasma PK population including all participants with three or more non-zero plasma concentrations. One participant withdrew on Day 7 and did not meet the requisite samples required for this PK parameter.</population>
        <group_list>
          <group group_id="O1">
            <title>0.65 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
          </group>
          <group group_id="O2">
            <title>1.3 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>The Ratio of AUC0-t to AUCinf</title>
          <description>Comparison of AUC0-t to AUCinf by creating a ratio.</description>
          <population>Plasma PK population including all participants with three or more non-zero plasma concentrations. One participant withdrew on Day 7 and did not meet the requisite samples required for this PK parameter.</population>
          <units>ratio of AUC0-t / AUCinf</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9741" spread="0.00862"/>
                    <measurement group_id="O2" value="0.9715" spread="0.01158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Half-life (t ½)</title>
        <description>Apparent first-order terminal elimination half life</description>
        <time_frame>Day 1 or Day 8 (before dosing and at the following times thereafter: 0.5, 0.75, 1, 2, 2.5, 3.0, 3.5, 4, 5, 6, 10, 14, and 24 hours post-dose)</time_frame>
        <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>0.65 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
          </group>
          <group group_id="O2">
            <title>1.3 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-life (t ½)</title>
          <description>Apparent first-order terminal elimination half life</description>
          <population>Plasma PK population includes all participants with at least one quantifiable PK concentration.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="1.194"/>
                    <measurement group_id="O2" value="5.42" spread="1.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Treatment-emergent AEs are summarized by total participants with TEAEs, participants with serious TEAEs, participants with TEAEs deemed by the investigator to be related to treatment, and participants who experienced TEAEs that caused permanent discontinuation from the study.</description>
        <time_frame>Day 1 up to week 4</time_frame>
        <population>The Safety Population consisted of all randomized participants who received at least one dose of tranexamic acid.</population>
        <group_list>
          <group group_id="O1">
            <title>0.65 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
          </group>
          <group group_id="O2">
            <title>1.3 g Tranexamic Acid</title>
            <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Treatment-emergent AEs are summarized by total participants with TEAEs, participants with serious TEAEs, participants with TEAEs deemed by the investigator to be related to treatment, and participants who experienced TEAEs that caused permanent discontinuation from the study.</description>
          <population>The Safety Population consisted of all randomized participants who received at least one dose of tranexamic acid.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with treatment-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with TEAEs causing discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to week 4</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.65 g Tranexamic Acid</title>
          <description>Participants were treated with a single dose of 0.65 g tranexamic acid.</description>
        </group>
        <group group_id="E2">
          <title>1.3 g Tranexamic Acid</title>
          <description>Participants were treated with a single dose of 1.3 g tranexamic acid.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript. Additional time may be required to allow Ferring to seek patent protection of the invention.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

